TERMINATION of treatmentACADEMIC medical centersHAIR folliclesHYDROXYCHLOROQUINEBackground: Lichen planopilaris (LPP) is an inflammatory cicatricial alopecia characterized by an irreversible destruction of the hair follicle resulting in its permeant destruction. The clinical presentation of LPP is a prog...
Causes of Lichen Planopilaris The precise cause of Lichen Planopilaris is not known and thus this makes the treatment a challenge. There are certain suspicions that point to autoimmunity as the cause of this disease. The immune system of the body reacts in an abnormal manner and mistakenly att...
Lichen planopilaris (LPP) is an inflammatory cicatricial alopecia for which many different therapies are attempted with varying success. The Janus kinase (JAK) inhibitor, tofacitinib, has been shown to be effective in treating the noncicatricial alopecia, alopecia areata. As in alopecia areata, upre...
Intoduction: Lichen planopilaris is an inflammatory lymphocyte mediated disorder in which INF-γ pathway fulfills an important role. Since JAKs are involved in the transduction of INF-γ signals their inhibition may be a good target for LPP treatment. Data on the efficacy of JAK-inhibitors on LP...
lichen planopilarismycophenolate mofetiltreatmentFor both patients and clinicians, lichen planopilaris (LPP) is a very challenging disease. Clinically and histologically, we observe active inflammation and disease progression, but our safe and simple anti-inflammatory medications often prove to be woefully ...
lichen planopilarismethotrexatescarring alopeciatherapyBackground: Because of irreversible outcome of the lichen planopilaris (LPP), systemic therapy should be used in early inflammatory stages of the disease, without allowing the irreversible scar formation and permanent hair loss.Objective: We assessed ...
LB1667 Successful treatment of rare linear lichen planopilaris with ixekizumabAbstractdoi:10.1016/j.jid.2023.06.039H. AhmedHamad Medical Corporation, Doha, Ad Dawhah, QatarM. PetkarHamad Medical Corporation, Doha, Ad Dawhah, QatarM. Steinhoff
lichen planopilarisscarring alopeciatofacitinibJanus kinase family (JAKs) has recently attracted the attention of many researchers, and several JAK inhibitor drugs have been developed targeting different members of the JAK family. Tofacitinib and ruxolitinib are U.S. FDA approved drugs in this family ...
HairAlopeciaScarring alopeciaCicatricial alopeciaLichen planopilarisFrontal fibrosing alopeciaNaltrexoneTreatmentTherapydoi:10.1007/s00403-024-03360-yPerez, Sofia M.Nguyen, BettyTosti, AntonellaSpringer Berlin HeidelbergArchives of Dermatological Research
treatmentLichen planopilaris (LPP) is an immune-mediated cicatricial alopecia. The main clinical presentations of LPP include classic form, frontal fibrosing alopecia (FFA), and Graham-Little-Piccardi-Lassueur syndrome (GLPLS). We reviewed medical records of all 291 patients diagnosied with LPP ...